NCT06743581View on ClinicalTrials.gov

Phase I/II Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer

NANot yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2030

Conditions
Non-Small Cell Lung CancerImmunotherapyNeoadjuvant Therapy
Interventions
DRUG

Cemiplimab

Cemiplimab 350 mg administered intravenously on day 1

DRUG

Dupilumab

Dupilumab 600 mg administered subcutaneously on day 1

Trial Locations (1)

H2X 3E4

Centre hospitalier de l'Université de Montréal (CHUM), Montreal

All Listed Sponsors
lead

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER